Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorTay Wee Teck, Joseph B.
dc.contributor.authorBaldacchino, Alexander M.
dc.contributor.authorGibson, Lauren
dc.contributor.authorLafferty, Con
dc.date.accessioned2021-03-23T09:30:03Z
dc.date.available2021-03-23T09:30:03Z
dc.date.issued2021-03-23
dc.identifier272156892
dc.identifierea983829-f07c-49df-8b9b-a52ff5aaa04f
dc.identifier85103756212
dc.identifier000636990600001
dc.identifier.citationTay Wee Teck , J B , Baldacchino , A M , Gibson , L & Lafferty , C 2021 , ' Using microdosing to induct patients into a long-acting injectable buprenorphine depot medication in low threshold community settings : a case study ' , Frontiers in Pharmacology , vol. 12 , 631784 . https://doi.org/10.3389/fphar.2021.631784en
dc.identifier.issn1663-9812
dc.identifier.otherORCID: /0000-0002-5388-7376/work/91341068
dc.identifier.urihttps://hdl.handle.net/10023/21686
dc.description.abstractHealthcare innovation has never been more important as it is now when the world is facing up to the unprecedented challenges brought by the COVID-19 pandemic. Within addictions services in Scotland, the priority has been to tackle our rising drug related death rate by maintaining and improving access to treatment while protecting frontline workers and managing operational challenges as a result of the pandemic. We present here a case study of five patients with opioid use disorder whose treatment represents a confluence of three important Medication Assisted Treatment (MAT) service innovations. The first was a low threshold drop in and outreach MAT service to rapidly and safely initiate opiate replacement therapy (ORT). The second was the provision of a microdosing regimen to enable same day induction to oral buprenorphine while minimizing the risk of precipitated opioid withdrawals and/or treatment disengagement. The third was rapid transitioning to an injectable long-acting buprenorphine depot which reduced unnecessary face to face patient contact and treatment non-adherence. This case study of five patients highlights the valuable role that buprenorphine microdosing can play in making induction to long-acting buprenorphine depot feasible to a broader range of patients, including those on a high dose methadone treatment regime.
dc.format.extent8
dc.format.extent628928
dc.language.isoeng
dc.relation.ispartofFrontiers in Pharmacologyen
dc.subjectBuprenorphine (BN)en
dc.subjectOpioid Use Disorder (OUD)en
dc.subjectMicrodosingen
dc.subjectDrug related deathsen
dc.subjectOutreachen
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectNDASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRA0421en
dc.titleUsing microdosing to induct patients into a long-acting injectable buprenorphine depot medication in low threshold community settings : a case studyen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Population and Behavioural Science Divisionen
dc.contributor.institutionUniversity of St Andrews. Centre for Minorities Research (CMR)en
dc.identifier.doi10.3389/fphar.2021.631784
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record